MYCN and cancer: A relatively high frequency of overexpression of MYC was observed in kidney (48%) and colorectal (37%) cancers; of MYCL (variants 1 and 2) in uterine (58%) and breast (40%) cancers; and of MYCN in uterine (58%), liver (44%), and ovarian (43%) cancers.